Drug intelligence / Profile preview

OT-S00X

Development stage: Unknown
Lead developer: Onward Therapeutics
Modality: Small Molecules

Overview

**OT-S00X** is a small molecule program targeting tumor onco-metabolism, specifically modulating chromatin-bound MDM2 (cMDM2) independently of p53 to overcome cancer resistance. Developed through a collaboration between Onward Therapeutics and Institut du Cancer de Montpellier (ICM), with involvement from Inserm and Université de Montpellier, it has demonstrated strong preclinical efficacy correlating with predictive biomarkers across multiple tumor types. The program is in lead optimization, utilizing AI to enhance compound properties, with plans to nominate IND-enabling candidates in 2026.[1][2][10]

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on OT-S00X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-S00X.

Explore the full profile